Digital PCR (dPCR) is an excellent tool for rare target analysis applications because, unlike traditional PCR methods, dPCR divides samples into thousands of individual microreactions, then ...

The stars have aligned for Bristol Myers Squibb and Orbital Therapeutics. | The stars have aligned for Bristol Myers Squibb ...

Kernal has been awarded up to $48M funding to accelerate the development of KR-402, a next-generation in vivo CAR T-cell ...

BMS, which already has two FDA-approved CAR T-cell therapies, is eyeing entry into the growing in vivo market.

(Reuters) -Drugmaker Bristol Myers Squibb said on Friday it will acquire privately held cell therapy developer Orbital ...

As the many challenges facing cell therapies are being addressed, the CAR T field continues to evolve beyond its original ...

Explore how regenerative medicine is transforming healing and restoration in healthcare, and discover its potential benefits ...

Researchers at the First Affiliated Hospital of the University of Science and Technology of China claim that an in vivo CD8 T ...

Investor reaction to the deal was muted, with BMO Capital Markets analysts saying they "continue to look for more" from ...

SHENZHEN, China, Sept. 17, 2025 /PRNewswire/ -- MagicRNA, a clinical-stage biotechnology company pioneering in vivo CAR T-cell therapies, today announced the publication of the world's first clinical ...

Researchers at MIT and Harvard have developed CAR-NK cells, which could lead to more effective cancer treatment.